Tyra Biosciences is expected to report a Q3 2026 consensus loss of $0.66 per share on $0 revenue, with its current $21.15 share price trading significantly below the average analyst target of $47.45.

Investors are primarily focused on clinical pipeline updates for dabogratinib (TYRA-300), particularly management's commentary on the BEACH301 study for achondroplasia following initial results from the SURF302 bladder cancer trial.

The company significantly strengthened its balance sheet with a $400 million underwritten offering in September 2026, extending its cash runway well into the second half of 2028. Wall Street will be scrutinizing the rate of R&D spend as the company advances multiple Phase 2 programs simultaneously.